Highlights: -In BEST, surgery is still top option for multivessel disease -Two-year data “suggest CoreValve should be preferred option for high-risk patients” -Wayne Batchelor: Closing the data gap -Martin Cowie: SERVE-HF -Profile: Deepak L Bhatt
[pdfviewer width=”100%” height=”940px” beta=”true”]http://cardiovascularnews.com/wp-content/uploads/sites/14/2016/06/37-Cardiovascular-News_low-res_EU.pdf[/pdfviewer]
